99 related articles for article (PubMed ID: 23759730)
1. Putting GWAS to the functional test: NR5A2 and pancreatic cancer risk.
Murtaugh LC
Gut; 2014 Apr; 63(4):535-6. PubMed ID: 23759730
[No Abstract] [Full Text] [Related]
2. Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation.
von Figura G; Morris JP; Wright CV; Hebrok M
Gut; 2014 Apr; 63(4):656-64. PubMed ID: 23645620
[TBL] [Abstract][Full Text] [Related]
3. Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRas(G12V)-driven pancreatic tumourigenesis.
Flandez M; Cendrowski J; Cañamero M; Salas A; del Pozo N; Schoonjans K; Real FX
Gut; 2014 Apr; 63(4):647-55. PubMed ID: 23598351
[TBL] [Abstract][Full Text] [Related]
4. NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas.
Chen NM; Singh G; Koenig A; Liou GY; Storz P; Zhang JS; Regul L; Nagarajan S; Kühnemuth B; Johnsen SA; Hebrok M; Siveke J; Billadeau DD; Ellenrieder V; Hessmann E
Gastroenterology; 2015 May; 148(5):1024-1034.e9. PubMed ID: 25623042
[TBL] [Abstract][Full Text] [Related]
5. Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy.
Kong B; Bruns P; Behler NA; Chang L; Schlitter AM; Cao J; Gewies A; Ruland J; Fritzsche S; Valkovskaya N; Jian Z; Regel I; Raulefs S; Irmler M; Beckers J; Friess H; Erkan M; Mueller NS; Roth S; Hackert T; Esposito I; Theis FJ; Kleeff J; Michalski CW
Gut; 2018 Jan; 67(1):146-156. PubMed ID: 27646934
[TBL] [Abstract][Full Text] [Related]
6. [Significance of ras mutations in pancreatic diseases].
Löhr M; Liebe S; Lowenfels AB
Z Gastroenterol; 1998 Oct; 36(10):929-32. PubMed ID: 9846373
[No Abstract] [Full Text] [Related]
7. A novel experimental model for human mixed acinar-ductal pancreatic cancer.
Doiron B; DeFronzo RA
Carcinogenesis; 2018 Feb; 39(2):180-190. PubMed ID: 29106450
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.
Stelow EB; Shaco-Levy R; Bao F; Garcia J; Klimstra DS
Am J Surg Pathol; 2010 Apr; 34(4):510-8. PubMed ID: 20182344
[TBL] [Abstract][Full Text] [Related]
9. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
[TBL] [Abstract][Full Text] [Related]
10. Induction of p21 and nuclear accumulation of TAp73alpha and c-abl during apoptosis of cisplatin-treated primary pancreatic acinar cells.
Sphyris N; Morris RG; Harrison DJ
Int J Oncol; 2004 Dec; 25(6):1661-70. PubMed ID: 15547703
[TBL] [Abstract][Full Text] [Related]
11. Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation.
Benod C; Vinogradova MV; Jouravel N; Kim GE; Fletterick RJ; Sablin EP
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):16927-31. PubMed ID: 21949357
[TBL] [Abstract][Full Text] [Related]
12. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
13. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.
Chen NM; Neesse A; Dyck ML; Steuber B; Koenig AO; Lubeseder-Martellato C; Winter T; Forster T; Bohnenberger H; Kitz J; Reuter-Jessen K; Griesmann H; Gaedcke J; Grade M; Zhang JS; Tsai WC; Siveke J; Schildhaus HU; Ströbel P; Johnsen SA; Ellenrieder V; Hessmann E
Gastroenterology; 2017 May; 152(6):1507-1520.e15. PubMed ID: 28188746
[TBL] [Abstract][Full Text] [Related]
14. ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis.
Wang L; Yang H; Abel EV; Ney GM; Palmbos PL; Bednar F; Zhang Y; Leflein J; Waghray M; Owens S; Wilkinson JE; Prasad J; Ljungman M; Rhim AD; Pasca di Magliano M; Simeone DM
Genes Dev; 2015 Jan; 29(2):171-83. PubMed ID: 25593307
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy: Targeting mitochondria in pancreatic cancer.
Errico A
Nat Rev Clin Oncol; 2014 Oct; 11(10):562. PubMed ID: 25155173
[No Abstract] [Full Text] [Related]
16. [KRAS mutation assay on EUS-FNA specimens from pacients with pancreatic mass].
Bunganič B; Hálková T; Benešová L; Belšánová B; Laclav M; Hrůzová M; Traboulsi E; Frič P; Suchánek Š; Minárik M; Zavoral M
Cas Lek Cesk; 2016; 155(1):48-51. PubMed ID: 26898792
[TBL] [Abstract][Full Text] [Related]
17. MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors.
Chio II; Yordanov G; Tuveson D
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25430851
[No Abstract] [Full Text] [Related]
18. FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth.
Kayed H; Kleeff J; Kolb A; Ketterer K; Keleg S; Felix K; Giese T; Penzel R; Zentgraf H; Büchler MW; Korc M; Friess H
Int J Cancer; 2006 Jan; 118(1):43-54. PubMed ID: 16003754
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Cancer: A Review.
Yabar CS; Winter JM
Gastroenterol Clin North Am; 2016 Sep; 45(3):429-45. PubMed ID: 27546841
[TBL] [Abstract][Full Text] [Related]
20. Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53.
Swidnicka-Siergiejko AK; Gomez-Chou SB; Cruz-Monserrate Z; Deng D; Liu Y; Huang H; Ji B; Azizian N; Daniluk J; Lu W; Wang H; Maitra A; Logsdon CD
Oncogene; 2017 Jun; 36(22):3149-3158. PubMed ID: 27991926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
